MARKET

CHMA

CHMA

Chiasma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.720
-0.090
-2.36%
After Hours: 3.690 -0.03 -0.81% 18:51 10/28 EDT
OPEN
3.760
PREV CLOSE
3.810
HIGH
3.850
LOW
3.690
VOLUME
452.69K
TURNOVER
--
52 WEEK HIGH
7.75
52 WEEK LOW
2.880
MARKET CAP
215.02M
P/E (TTM)
-2.7549
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Crinetics Pharma lead drug successful in mid-stage acromegaly study
A Phase 2 clinical trial, ACROBAT Edge, evaluating Crinetics Pharmaceuticals' (CRNX) lead candidate paltusotine (formerly CRN00808) for the treatment of acromegaly met the primary endpoint. Specifically, once-daily oral doses of
Seekingalpha · 2d ago
CORR, FATE, AKBA and DPW among after-hours movers
Gainers: [[AKBA]] +8%. [[FATE]] +5%. [[CHMA]] +3.5%. [[UAVS]] +3%. [[ZAGG]] +2%.Losers: [[KLIC]] -5.1%. [[ACRS]] -4.6%. [[LITB]] -2.9%. [[CORR]] -2.6%. [[DPW]] -1.3%.
Seekingalpha · 10/09 21:41
Chiasma finance chief to depart
Chiasma (CHMA) reports that President and Principal Financial Officer Mark Fitzpatrick intends to step down. He will remain on the job until no later than June 30, 2021 to ensure
Seekingalpha · 10/01 11:08
Chiasma Announces Planned Transition Of Former CEO
NEEDHAM, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to reduce
Benzinga · 10/01 11:06
3 “Strong Buy” Healthcare Stocks Under $5 With Triple-Digit Growth Prospects
For those that thought the extreme market volatility was behind us, think again. This month, another burst of volatility was brought on by concerns about the U.S. economic recovery, hefty valuations, and a second wave of COVID-19. While challenging at times, Wall Street pros believe the healthcare space
TipRanks · 09/24 14:46
Chiasma to Participate in Two September Investor Conferences
NEEDHAM, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to reduce the burden of chronic injections for people with rare diseases, today announced that management
GlobeNewswire · 09/08 13:00
Crinetics Pharmaceuticals- Superior Molecules In Endocrinology
Crinetics Pharmaceuticals (CRNX) is a clinical stage company focused on in house synthesis of novel molecules for rare endocrine diseases.
Seeking Alpha - Article · 09/01 17:35
Chiasma announces U.S. commercial launch and availability of MYCAPSSA
Chiasma ([[CHMA]] -0.7%) has launched MYCAPSSA capsules in the United States for patients with acromegaly.MYCAPSSA, the first and only oral somatostatin analog approved by the U.S. Food and Drug Administration
Seekingalpha · 08/31 13:39
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CHMA. Analyze the recent business situations of Chiasma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CHMA stock price target is 13.60 with a high estimate of 19.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 123
Institutional Holdings: 32.07M
% Owned: 55.48%
Shares Outstanding: 57.80M
TypeInstitutionsShares
Increased
32
1.36M
New
40
-1.48M
Decreased
17
1.38M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-2.08%
Pharmaceuticals & Medical Research
-2.11%
Key Executives
Chairman/Director
David Stack
President/Chief Financial Officer
Mark Fitzpatrick
Chief Executive Officer/Director
Raj Kannan
Executive Vice President
Anand Varadan
Executive Vice President
anand Varadan
Senior Vice President
William Ludlam
Chief Accounting Officer/Vice President - Finance/Vice President - Administration
Drew Enamait
Vice President/General Counsel/Secretary
Lee Giguere
Director
Roni Mamluk
Independent Director
Todd Foley
Independent Director
Bard Geesaman
Independent Director
Scott Minick
Independent Director
John Scarlett
Independent Director
John Thero
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CHMA
Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company's TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Chiasma Inc stock information, including NASDAQ:CHMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CHMA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CHMA stock methods without spending real money on the virtual paper trading platform.